2,2'-Bipyridyl-6-carbothioamide derivatives as potential antitumor agents.
4- and/or 4'-substituted 2,2'-bipyridyl-6-carbothioamides have been synthesized and tested for their activity against P-388 lymphocytic leukemia in mice. Of these, only 4'-nitro-2,2'-bipyridyl-6-carbotioamide (IV c) proved to be active.